cept Therapeutics rporated(CORT) Prnewswire·2025-03-03 18:25Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated regarding potential securities fraud or unlawful business practices [1] - A lawsuit has been filed against Corcept by a group of health insurers, alleging manipulation of the patent process to hinder Teva Pharmaceutical's generic product launch of Korlym [2] - Following the news of the lawsuit, Corcept's stock price experienced a significant decline of 65.09 per share [3] Company Overview - Corcept Therapeutics is known for its product Korlym, which has been a best-seller in its category [2] - The company is facing legal challenges that may impact its market position and stock performance [2][3] Legal Context - The lawsuit against Corcept highlights ongoing tensions in the pharmaceutical industry regarding patent enforcement and competition from generic drugs [2] - Pomerantz LLP, a prominent firm in corporate and securities litigation, is leading the investigation into Corcept's practices [1][4]